FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021837487> ?p ?o ?g. }

• W2021837487 endingPage "1500" @default.
• W2021837487 startingPage "1497" @default.
• W2021837487 abstract "actinic keratoses basal cell carcinoma confidence interval least-squares squamous cell carcinoma Nicotinamide (vitamin B3) prevents photocarcinogenesis in mice (Gensler et al., 1999Gensler H.L. Williams T. Huang A.C. et al.Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice.Nutr Cancer. 1999; 34: 36-41Crossref PubMed Scopus (93) Google Scholar) and photoimmunosuppression in humans (Damian, 2010Damian D.L. Photoprotective effects of nicotinamide (invited review).Photochem Photobiol Sci. 2010; 9: 578-585Crossref PubMed Scopus (34) Google Scholar). Actinic keratoses (AKs) strongly predict non-melanoma skin cancer risk (Green and Battistutta, 1990Green A. Battistutta D. Incidence and determinants of skin-cancer in a high-risk Australian population.Int J Cancer. 1990; 46: 356-361Crossref PubMed Scopus (213) Google Scholar). These phase II studies aimed to determine whether oral nicotinamide, at different doses, reduced AKs in sun-damaged individuals. Healthy, immune-competent volunteers with ≥4 palpable AKs (face, scalp and upper limbs) were recruited from Royal Prince Alfred Hospital Dermatology Clinics, Sydney, Australia. The study protocols (ACTRN12609000490279; ACTRN12610000689077; http://www.anzctr.org.au) adhered to Helsinki Guidelines and were approved by the Sydney South West Area Health Service and University of Sydney ethics committees. All volunteers provided written informed consent. Participants were randomly assigned (1:1) to take nicotinamide 500mg (Nature's Own, Virginia, Queensland, Australia) or matched placebo (Australian Custom Pharmaceuticals, Sydney, New South Wales, Australia) twice daily (Study 1) or once daily (Study 2) for 4 months. The treatment allocation sequence was determined by a computer-generated randomization list prepared using a permuted blocks method (block size 6) by an investigator (DLD) not involved in AK assessment. Participants underwent complete skin examination before randomization, were encouraged to use daily sunscreen, and remained blinded throughout the study. At baseline, 2 and 4 months, palpable AKs were identified visually and by touch by a blinded observer (DS), counted and documented on a body grid chart. At baseline and 2 months, full blood count, creatinine, and liver function were assessed. A target of 36 patients was selected for Study 1 based on clinical judgement as this was our first pilot trial of oral nicotinamide. A conservative interpretation of the Study 1 results was used to inform the assumptions used in the sample size calculation for Study 2, where a sample size was selected to provide ≥80% power to detect a standardized effect size of 0.4 at the two-sided 5% level of significance, based on an analysis of covariance model given a correlation of 0.90 between baseline and follow-up assessments (Borm et al., 2007Borm G.F. Fransen J. Lemmens W.A.J.G. A simple sample size formula for analysis of covariance in randomized clinical trials.J Clin Epidemiol. 2007; 60: 1234-1238Abstract Full Text Full Text PDF PubMed Scopus (329) Google Scholar), allowing for 5% withdrawal. All randomized patients were eligible for inclusion in the efficacy analysis (intention to treat). The primary endpoint obtained for each patient was the AK count at 4 months. We also noted all histologically confirmed skin cancers during the study. The right-skewed distribution of the AK data was rectified by applying a loge transformation (with results back-transformed for reporting). The relative difference between groups on AK count was estimated using an analysis of covariance adjusting for baseline (Bonate, 2000Bonate P.L. Analysis of Pretest-Postest Designs. Chapman & Hall/CRC, Boca Raton, Florida, USA2000Crossref Google Scholar). Logistic and Poisson regression was used to compare treatment groups from both studies combined on skin cancer incidence with the number of previous cancers and study designation fitted as covariates. A total of 35 patients were enrolled in Study 1 (June–October 2009) (Table 1). One withdrew (nicotinamide) at 2 months because of invasive squamous cell carcinoma (SCC), but returned for his 4-month AK count. A total of 41 patients were enrolled in Study 2 (August–November 2010); two withdrew from treatment (placebo) soon after their baseline counts because of nursing-home placement, but agreed to follow up AK counts. Two nicotinamide participants withdrew from follow-up for personal reasons soon after enrolment; their baseline AK counts were carried forward and included in the primary analysis (Figures 1 and 2).Table 1Baseline characteristics and AKs during treatment with nicotinamide or placeboStudy 1 (500mg b.d.)Study 2 (500mg o.d.)PlaceboNicotinamidePlaceboNicotinamidePatients enrolled17182021Men:women10.715.314:614:7Mean age (years; range)72 (52–90)71 (59–82)72 (48–89)67 (52–80)Total AKs at baseline Mean (SD)31.5 (21.1)29.3 (23.5)40.3 (26.5)30.6 (16.3) Range (median)9–92 (23)6–89 (19)7–101 (37)12–73 (27)Total AKs at 2 months Mean (SD)28.2 (20.7)18.1 (16.8)35.5 (23.1)24.3 (14.6) Range (median)6–91 (20)3–65 (11)5–99 (34)4–60 (21) LS mean (95% CI)1Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a covariate. The absolute difference between the groups on loge(AK count) corresponds to the relative difference between the groups on AK count.20.9 (18.5-23.5)13.6 (12.1-15.3)26.1 (23.2–29.4)22.1 (19.7–24.8)Relative reduction (95% CI)1Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a covariate. The absolute difference between the groups on loge(AK count) corresponds to the relative difference between the groups on AK count.35% (23–45%)15% (0–28%) P-value<0.00010.046Total AKs at 4 months Mean (SD)27.1 (19.9)16.6 (13.9)34.8 (20.9)21.6 (14.7) Range (median)6–89 (20)2–54 (10)5–89 (32)3–60 (18) LS mean (95% CI)1Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a covariate. The absolute difference between the groups on loge(AK count) corresponds to the relative difference between the groups on AK count.19.9 (16.9–23.4)12.9 (11.0–15.2)25.9 (21.9–30.6)18.3 (15.6–21.6)Relative reduction (95% CI)1Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a covariate. The absolute difference between the groups on loge(AK count) corresponds to the relative difference between the groups on AK count.35% (18–48%)29% (11–44%) P-value2Very similar P-values were obtained in a sensitivity analysis when the groups were compared on percentage change from baseline at month 4 in AK count (statistical problems associated with using percentage change as an endpoint and rationale for statistical adjustment of baseline scores via analysis of covariance as the optimal analysis approach reviewed in Bonate (2000)).0.00060.005Abbreviations: AKs, actinic keratoses; CI, confidence interval; LS, least squares.Bold values indicate means and significant P-values.1 Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a covariate. The absolute difference between the groups on loge(AK count) corresponds to the relative difference between the groups on AK count.2 Very similar P-values were obtained in a sensitivity analysis when the groups were compared on percentage change from baseline at month 4 in AK count (statistical problems associated with using percentage change as an endpoint and rationale for statistical adjustment of baseline scores via analysis of covariance as the optimal analysis approach reviewed in Bonate, 2000Bonate P.L. Analysis of Pretest-Postest Designs. Chapman & Hall/CRC, Boca Raton, Florida, USA2000Crossref Google Scholar). Open table in a new tab Figure 2CONSORT 2010 flow diagram, study 2: nicotinamide 500mg daily versus placebo.View Large Image Figure ViewerDownload (PPT) Abbreviations: AKs, actinic keratoses; CI, confidence interval; LS, least squares. Bold values indicate means and significant P-values. AK counts at baseline and follow-up are shown in the Table 1. A 35% relative reduction in AK count at 4 months (95% confidence interval (CI): 18–48%; P=0.0006) was estimated from Study 1 (with similar results at 2 months). A 29% relative reduction in AK count at 4 months (95% CI: 11–44%; P=0.005) was estimated from Study 2 (with smaller but significant differences observed at 2 months). There was no evidence that the relative effect of nicotinamide was modified by baseline AK count (treatment-by-baseline interaction P-value was nonsignificant). For Studies 1 and 2 combined, 37 patients were randomized to placebo and 37 to nicotinamide. Eighty-one and 79% of placebo and nicotinamide patients, respectively, had previous, histologically confirmed skin cancers. During the 4-month trials, 11 placebo patients developed 20 new skin cancers (12 basal cell carcinoma (BCC) and 8 SCC) and 2 nicotinamide patients developed 4 cancers (2 BCC and 2 SCC). The odds of developing at least one skin cancer was significantly lower with nicotinamide (odds ratio=0.14; 95% CI: 0.03–0.73, P=0.019) as was the rate of new skin cancers (relative rate=0.24; 95% CI: 0.08–0.71, P=0.010) as estimated, respectively, by Logistic and Poisson regression models and adjusting for study and number of previous skin cancers. The treatment effect remained significant when analysis of skin cancer rates was repeated using a negative binomial model (P=0.038), although we note the unplanned nature of this combined analysis. Compliance, measured by counts of returned tablets, was 94–98%. One patient, who was also taking aspirin, described nausea while taking nicotinamide. No other potential side effects were reported and no clinically significant changes in blood profiles were observed. The mechanisms by which nicotinamide might prevent skin cancer or reduce progression of subclinical lesions are unclear. Nicotinamide is a substrate and inhibitor of the nuclear enzyme poly-ADP-ribose polymerase, which is centrally involved in DNA repair (Virag and Szabo, 2002Virag L. Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.Pharmacol Rev. 2002; 54: 375-429Crossref PubMed Scopus (1223) Google Scholar). As a precursor of nicotinamide adenine dinucleotide, nicotinamide prevents the decline in cellular energy observed after UV exposure (Park et al., 2010Park J. Halliday G.M. Surjana D. et al.Nicotinamide prevents ultraviolet radiation-induced cellular energy loss.Photochem Photobiol. 2010; 86: 942-948Crossref PubMed Scopus (95) Google Scholar), and could therefore maintain efficient DNA repair. Immunosuppression has a key role in the malignant transformation of AKs (Frost and Green, 1994Frost C.A. Green A.C. Epidemiology of solar keratoses.Br J Dermatol. 1994; 131: 455-464Crossref PubMed Scopus (233) Google Scholar), and nicotinamide is highly immune protective in humans (Damian et al., 2008Damian D.L. Patterson C.R.S. Stapelberg M. et al.Ultraviolet radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide.J Invest Dermatol. 2008; 128: 447-454Abstract Full Text Full Text PDF PubMed Scopus (170) Google Scholar). Hence, nicotinamide protection from photoimmunosuppression (Yiasemides et al., 2009Yiasemides E. Sivapirabu G. Halliday G.M. et al.Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans.Carcinogen. 2009; 30: 101-105Crossref PubMed Scopus (98) Google Scholar) may be a key mediator of the reduction in AKs observed here. Spontaneous fluctuation in AK counts has been previously reported (Criscione et al., 2009Criscione V.D. Weinstock M.A. Naylor M.F. et al.Actinic keratoses natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.Cancer. 2009; 115: 2523-2530Crossref PubMed Scopus (314) Google Scholar; Moloney et al., 2010Moloney F.J. Vestergaard M.E. Radojkovic B.L. et al.Randomised, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses.Br J Dermatol. 2010; 162: 1138-1139Crossref PubMed Scopus (28) Google Scholar), consistent with the 13–15% reduction from baseline observed in our placebo groups. Our randomized, double-blinded design enabled detection of AK reductions with nicotinamide relative to any background variations in AKs due to seasonal and behavioral fluctuations in UV doses. Nicotinamide is well tolerated and costs $5–$10 per month at the doses used here. The results of these phase II studies suggest nicotinamide is effective in reducing AKs and shows promise for skin cancer chemoprevention. A longer phase III trial in a larger cohort, with new skin cancers as the primary endpoint, is now warranted. We are most thankful to our study participants, and gratefully acknowledge the funding of the Cancer Council New South Wales, Epiderm, and the Dermatology Research Foundation." @default.
• W2021837487 created "2016-06-24" @default.
• W2021837487 creator A5019636461 @default.
• W2021837487 creator A5040089794 @default.
• W2021837487 creator A5043017139 @default.
• W2021837487 creator A5069909741 @default.
• W2021837487 creator A5086460858 @default.
• W2021837487 date "2012-05-01" @default.
• W2021837487 modified "2023-10-14" @default.
• W2021837487 title "Oral Nicotinamide Reduces Actinic Keratoses in Phase II Double-Blinded Randomized Controlled Trials" @default.
• W2021837487 cites W1988408744 @default.
• W2021837487 cites W1997179621 @default.
• W2021837487 cites W2008066214 @default.
• W2021837487 cites W2044030923 @default.
• W2021837487 cites W2044367059 @default.
• W2021837487 cites W2053692867 @default.
• W2021837487 cites W2075012277 @default.
• W2021837487 cites W2084060660 @default.
• W2021837487 cites W2090512029 @default.
• W2021837487 cites W2099980697 @default.
• W2021837487 cites W2164807079 @default.
• W2021837487 doi "https://doi.org/10.1038/jid.2011.459" @default.
• W2021837487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22297641" @default.
• W2021837487 hasPublicationYear "2012" @default.
• W2021837487 type Work @default.
• W2021837487 sameAs 2021837487 @default.
• W2021837487 citedByCount "115" @default.
• W2021837487 countsByYear W20218374872012 @default.
• W2021837487 countsByYear W20218374872013 @default.
• W2021837487 countsByYear W20218374872014 @default.
• W2021837487 countsByYear W20218374872015 @default.
• W2021837487 countsByYear W20218374872016 @default.
• W2021837487 countsByYear W20218374872017 @default.
• W2021837487 countsByYear W20218374872018 @default.
• W2021837487 countsByYear W20218374872019 @default.
• W2021837487 countsByYear W20218374872020 @default.
• W2021837487 countsByYear W20218374872021 @default.
• W2021837487 countsByYear W20218374872022 @default.
• W2021837487 countsByYear W20218374872023 @default.
• W2021837487 crossrefType "journal-article" @default.
• W2021837487 hasAuthorship W2021837487A5019636461 @default.
• W2021837487 hasAuthorship W2021837487A5040089794 @default.
• W2021837487 hasAuthorship W2021837487A5043017139 @default.
• W2021837487 hasAuthorship W2021837487A5069909741 @default.
• W2021837487 hasAuthorship W2021837487A5086460858 @default.
• W2021837487 hasBestOaLocation W20218374871 @default.
• W2021837487 hasConcept C126322002 @default.
• W2021837487 hasConcept C142724271 @default.
• W2021837487 hasConcept C16005928 @default.
• W2021837487 hasConcept C181199279 @default.
• W2021837487 hasConcept C185592680 @default.
• W2021837487 hasConcept C204787440 @default.
• W2021837487 hasConcept C27081682 @default.
• W2021837487 hasConcept C2779728014 @default.
• W2021837487 hasConcept C2910086692 @default.
• W2021837487 hasConcept C2994504663 @default.
• W2021837487 hasConcept C3019992690 @default.
• W2021837487 hasConcept C55493867 @default.
• W2021837487 hasConcept C71924100 @default.
• W2021837487 hasConceptScore W2021837487C126322002 @default.
• W2021837487 hasConceptScore W2021837487C142724271 @default.
• W2021837487 hasConceptScore W2021837487C16005928 @default.
• W2021837487 hasConceptScore W2021837487C181199279 @default.
• W2021837487 hasConceptScore W2021837487C185592680 @default.
• W2021837487 hasConceptScore W2021837487C204787440 @default.
• W2021837487 hasConceptScore W2021837487C27081682 @default.
• W2021837487 hasConceptScore W2021837487C2779728014 @default.
• W2021837487 hasConceptScore W2021837487C2910086692 @default.
• W2021837487 hasConceptScore W2021837487C2994504663 @default.
• W2021837487 hasConceptScore W2021837487C3019992690 @default.
• W2021837487 hasConceptScore W2021837487C55493867 @default.
• W2021837487 hasConceptScore W2021837487C71924100 @default.
• W2021837487 hasIssue "5" @default.
• W2021837487 hasLocation W20218374871 @default.
• W2021837487 hasLocation W20218374872 @default.
• W2021837487 hasOpenAccess W2021837487 @default.
• W2021837487 hasPrimaryLocation W20218374871 @default.
• W2021837487 hasRelatedWork W1979149413 @default.
• W2021837487 hasRelatedWork W2017040711 @default.
• W2021837487 hasRelatedWork W2073472848 @default.
• W2021837487 hasRelatedWork W2162982036 @default.
• W2021837487 hasRelatedWork W2198714039 @default.
• W2021837487 hasRelatedWork W2417509913 @default.
• W2021837487 hasRelatedWork W2588294548 @default.
• W2021837487 hasRelatedWork W4244071458 @default.
• W2021837487 hasRelatedWork W4387351442 @default.
• W2021837487 hasRelatedWork W2588190670 @default.
• W2021837487 hasVolume "132" @default.
• W2021837487 isParatext "false" @default.
• W2021837487 isRetracted "false" @default.
• W2021837487 magId "2021837487" @default.
• W2021837487 workType "article" @default.